Aridhia Announces New Deal for RSRCH-Health Service in Netherlands
News Dec 01, 2016
Aridhia CEO, Chris Roche.
Scottish clinical and translational informatics company Aridhia, Netherlands-based ICT service provider Vancis, and clinical datasets experts MGRID have announced the expansion of their existing partnership with the launch of a new research platform service, RSRCH-Health, into the Netherlands.
The initiative will be introduced at the Health-RI conference on December 1st in Amersfoort, Netherlands to an audience of researchers, academics and clinicians who are being encouraged to work together to enable ground-breaking biomedical research.
The growth of Aridhia’s operations outside the UK follows the partnership agreement with Vancis announced in mid-2015. A number of new jobs in both Scotland and the Netherlands are expected to be created as a result of this collaboration.
Based on Aridhia’s AnalytiXagility data analysis platform, RSRCH-Health was first established in early 2016 to deliver a digital research environment to Radboudumc Nijmegen in a three-year deal, making it the first University Medical Centre in the Netherlands to offer a digital platform to all research teams across the institution.
Radboudumc is currently rolling out RSRCH-Health across the entire organisation, providing analytical workspaces for up to 1600 research projects to accelerate the delivery of research studies into clinical practice.
The extended Vancis, Aridhia, and MGRID collaboration - which goes by the name RSRCH - signifies continued growth for Aridhia, one of Scotland’s data science success stories.
Chris Roche, Aridhia’s CEO, said of the new company: “The development of AnalytiXagility into a tailored offering for the Netherlands’ market is very exciting for Aridhia and is validation that our platform is precisely what research-driven organisations need to achieve the best outcomes.
“Research teams worldwide are realising the value in wide-scale collaboration around data, and together with Vancis and MGRID, we believe that RSRCH-Health represents an answer to the data challenges that they face.”
Eli Berkelmans, RSRCH Managing Director said: “RSRCH-Health gives us the means to deliver a unique on-demand, secure platform service specifically catering to the needs of researchers.
“It is already being used at Radboudumc by a number of showcase projects and thanks to word-of-mouth, it is generating interest across Europe. We’re excited about the opportunities this opens up to us and, more importantly, to research teams worldwide.”
The RSRCH-Health platform incorporates Aridhia’s existing AnalytiXagility services with infrastructure expertise from Vancis, and MGRID’s Aperture which speeds up creation of datasets for clinical research, to deliver a self-service capability which answers the specific requirements of the Netherland’s market.
Developed to deliver rapid change by enabling a multidisciplinary, collaborative approach to biomedical research, RSRCH-Health is available via the Amsterdam based RSRCH team and is suitable for individual studies, or as the digital environment for all projects within a research-driven institution.
This partnership adds to Aridhia’s growing portfolio of European projects as it exports AnalytiXagility to prominent research collaborations across the continent, including the ground-breaking European Prevention of Alzheimer’s Dementia (EPAD) project, an Innovative Medicines Initiative funded research programme.
Original story from Aridhia. Please note: The content above may have been edited to ensure it is in keeping with Technology Networks' style and length guidelines.
Staphylococcus epidermidis is an ubiquitous colonizer of healthy human skin, but it is also a notorious source of serious nosocomial infections. Now, a new machine learning technique will help predict the risk of developing a serious, and possibly life-threatening S. epidermidis infection.READ MORE
In the largest study of its kind, researchers at Newcastle University have led national research into the treatment of patients with newly diagnosed myeloma. The results, published by The Lancet Oncology, show an improvement for those who received ongoing therapy with a drug called lenalidomide, compared to those not receiving it.READ MORE